CABA - Cabaletta Bio, Inc.
1.145
0.035 3.057%
Share volume: 1,085,634
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$1.11
0.03
0.03%
Fundamental analysis
21%
Profitability
0%
Dept financing
2%
Liquidity
50%
Performance
40%
Performance
5 Days
-3.78%
1 Month
-35.31%
3 Months
-50.65%
6 Months
-73.62%
1 Year
-93.65%
2 Year
-85.93%
Key data
Stock price
$1.14
DAY RANGE
$0.99 - $1.19
52 WEEK RANGE
$0.99 - $18.53
52 WEEK CHANGE
-$93.92
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
Company detail
CEO: Steven Nichtberger
Region: US
Website: www.cabalettabio.com
Employees: 50
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: www.cabalettabio.com
Employees: 50
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
Recent news
